Director Glenn P. Muir of Cytek Biosciences, Inc. filed a Statement of Changes in Beneficial Ownership on November 20, 2026, reporting an RSU vesting transaction in the company's common stock dated November 18, 2026.
Key Highlights
- Reporting person: Glenn P. Muir, identified as a Director of Cytek Biosciences, Inc.
- Transaction date: November 18, 2026, involving 4,629 shares of common stock acquired via RSU vesting (transaction code M).
- Post-transaction common stock ownership: 7,715 shares held directly following the reported transaction.
- RSU derivative position: 47,840 RSUs remain beneficially owned directly after the vesting event, at a price of $0.
- Vesting schedule: The RSU Award vests over 3 years according to a fractional schedule tied to multiple dates across 2026 and 2027.
- Filing signed: Wenbin Jiang, Attorney-in-Fact, on November 20, 2026.
Glenn Muir's RSU Vesting at Cytek Biosciences on November 18, 2026
According to the filing, Glenn P. Muir, a director of Cytek Biosciences, Inc. (NASDAQ:CTKB), reported the vesting of 4,629 Restricted Stock Units on November 18, 2026. Cytek Biosciences is a life science company whose common stock trades on NASDAQ under the symbol CTKB. Each RSU, as the filing states, "represents a contingent right to receive one share of the Issuer's common stock." The transaction was recorded under transaction code M, reflecting a conversion from derivative security to common stock.
Following the transaction, Muir directly held 7,715 shares of common stock and retained 47,840 RSUs as a direct derivative position. The filing reports the price of the derivative security as $0, consistent with standard RSU award mechanics where no exercise price is paid by the recipient upon vesting.
The filing describes a multi-date vesting schedule spanning three years. Specifically, 2/36 of the total RSU Award shares vested on August 18, 2026; 3/36 vested on November 18, 2026, and are set to vest on each subsequent November 18; 4/36 are scheduled to vest on March 10, 2027, and each March 10 thereafter; 3/36 on May 18, 2027, and each May 18 thereafter; and 3/36 on August 18, 2027, and each August 18 thereafter. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan.
What Was Disclosed
Cytek Biosciences director Glenn P. Muir disclosed the vesting of 4,629 RSUs into common stock on November 18, 2026, leaving him with 7,715 shares of common stock and 47,840 RSUs remaining directly held.




Please wait processing your request...